Swedish Orphan Drug Patent Portfolio
Swedish Orphan owns 1 orange book drug protected by 2 US patents Given below is the list of Swedish Orphan's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9301932 | Liquid pharmaceutical composition comprising nitisinone | 28 Feb, 2033 | Active |
| US5550165 | Pharmaceutical compositions for the treatment of hereditary tyosinemia type I | 27 Aug, 2013 | Expired |
Latest Legal Activities on Swedish Orphan's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Swedish Orphan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Sep, 2023 | US9301932 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Sep, 2019 | US9301932 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Apr, 2016 | US9301932 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Apr, 2016 | US9301932 |
|
Email Notification
Critical
| 17 Mar, 2016 | US9301932 |
|
Issue Notification Mailed
Critical
| 16 Mar, 2016 | US9301932 |
| Dispatch to FDC | 02 Mar, 2016 | US9301932 |
|
Application Is Considered Ready for Issue
Critical
| 02 Mar, 2016 | US9301932 |
|
Issue Fee Payment Received
Critical
| 23 Feb, 2016 | US9301932 |
|
Issue Fee Payment Verified
Critical
| 23 Feb, 2016 | US9301932 |
|
Mail Notice of Allowance
Critical
| 12 Feb, 2016 | US9301932 |
|
Email Notification
Critical
| 12 Feb, 2016 | US9301932 |
|
Electronic Review
Critical
| 12 Feb, 2016 | US9301932 |
|
Notice of Allowance Data Verification Completed
Critical
| 09 Feb, 2016 | US9301932 |
|
Information Disclosure Statement considered
Critical
| 05 Feb, 2016 | US9301932 |
Swedish Orphan's Family Patents
Swedish Orphan Drug List
Given below is the complete list of Swedish Orphan's drugs and the patents protecting them.
1. Orfadin
Orfadin is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9301932 | Liquid pharmaceutical composition comprising nitisinone |
28 Feb, 2033
(8 years from now)
| Active |
| US5550165 | Pharmaceutical compositions for the treatment of hereditary tyosinemia type I |
27 Aug, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orfadin's drug page